Monday, March 18, 2024 at 4:30pm ET
Moderated by Senda Ajroud-Driss, this webinar for both clinicians and people living with ALS will review the 3 drugs that are currently FDA-approved in the United States for the general ALS population. Panelists, Dr. Lauren Elman, Dr. John Novak, and Dr. Xiaowei (Bill) Su will present information on Riluzole, Radicava, and Relyvrio, including drug mechanism, findings from clinical trials, and potential benefits, risks, and costs.